Please login to the form below

Not currently logged in

Lilly's Alimta patent confirmed

A US District Court has confirmed the validity of Eli Lilly's patent for Alimta – a drug used in chemotherapy

The US District Court for the District of Delaware has confirmed the validity of Eli Lilly's patent for Alimta (pemetrexed) – a drug used in chemotherapy.

In the case of Eli Lilly and Company et al v. Teva Parenteral Medicines Inc, the court ruled that Lilly's patent provide protection for Alimta in the US until July 2016. The case followed Teva's abbreviated new drug application (ANDA) to manufacture a generic version of Alimta.

Alimta, used in the treatment of malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC), achieved global sales of $1.64bn over the first three quarters of 2010.

"We are pleased that the District Court has now confirmed the validity of Alimta's compound patent," said Robert A Armitage, senior vice president and general counsel for Lilly. "We continue to emphasise that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve.

"These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

16th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...